Thomas Meier
Founder bei SANTHERA PHARMACEUTICALS HOLDING AG
Vermögen: 152 196 $ am 31.03.2024
Profil
Dr. Thomas Meier is a Chairman at Santhera Pharmaceuticals Holding AG and a Managing Partner at Viopas Venture Consulting GmbH.
He is on the Board of Directors at Onconetix, Inc., Visgenx, Inc. and Novaremed AG.
Dr. Meier was previously employed as a Chief Executive Officer by MyoContract AG and a Chairman by PharmaBiome AG.
He received his graduate degree from the University of Basel and a doctorate degree from the University of Basel.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
31.12.2022 | 14 031 ( 0,11% ) | 152 196 $ | 31.03.2024 |
Aktive Positionen von Thomas Meier
Unternehmen | Position | Beginn |
---|---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Founder | 07.09.2004 |
ONCONETIX, INC. | Director/Board Member | 06.02.2024 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Director/Board Member | 01.05.2020 |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Director/Board Member | 01.01.2022 |
Ehemalige bekannte Positionen von Thomas Meier
Unternehmen | Position | Ende |
---|---|---|
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Chairman | 01.01.2021 |
MyoContract AG | Chief Executive Officer | 01.01.2004 |
Ausbildung von Thomas Meier
University of Basel | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
ONCONETIX, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
MyoContract AG | Health Technology |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |